SGD Pharma has released the latest expansion of its Sterinity range of Ready-To-Use (RTU) Type I moulded glass vials.
The vials are now available in sizes 10ml and 20ml in tray.
Demand for high-value parenteral drugs has increased dramatically in recent years, placing more pressure on pharmaceutical companies to accelerate their time to market.
SGD Pharma’s range of RTU Sterinity vials offer a solution to the lengthy stages of vial-sterilisation and provides the flexibility customers require to prioritise patient safety and distribute medicines substantially faster.
Furthermore, by outsourcing the sterilisation process, SGD Pharma’s compliant Sterinity range reduces total cost of ownership (TCO).
The Sterinity portfolio has been adapted to suit a wide variety of applications and accommodate the needs of many customer markets, including pharmaceutical and biopharmaceutical companies, compounding pharmacies, hospitals and veterinary clinics.
Carole Grassi Mircich, Chief Commercial Marketing and Innovation Officer, said: “SGD Pharma has a proven record of quickly addressing the evolving pharmaceutical packaging needs of its customers.
“Our Sterinity range extension comes at a time when global demand for parenteral drugs is at its peak. Our convenient new 10ml and 20ml ISO moulded glass vials in tray, provide an optimal packaging solution for biologics and innovative treatments that require glass vials for parenteral use.
“SGD Pharma will continue to innovate and produce high-quality primary glass packaging for our customers and partners, maintaining our position as global industry-leader.”
SGD Pharma has immediate stock availability of its new 10ml and 20ml Sterinity moulded glass vials, to ensure customer lead times are met.
Sterinity vials are also suitable for extreme conditions encountered during the lyophilisation process, as they combine the strength of moulded glass with aesthetics quality and weight reduction.
